Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1706
    +0.0012 (+0.11%)
     
  • GBP/USD

    1.2622
    +0.0000 (+0.00%)
     
  • Bitcoin GBP

    55,799.82
    +607.22 (+1.10%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,337.57
    +169.50 (+0.42%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Fresenius, Smiths in 2-way race for Pfizer infusion pumps-sources

By Arno Schuetze and Ludwig Burger

FRANKFURT, June 6 (Reuters) - German healthcare supplier Fresenius (Swiss: FRE.SW - news) and British engineering company Smiths Group (Other OTC: SMGKF - news) have emerged as the final bidders for Pfizer (NYSE: PFE - news) 's infusion pumps business in a possible deal worth close to $1.5 billion, people familiar with the matter said.

Pfizer is hiving off the business, which it acquired as part of the $16 billion takeover of Hospira (NYSE: HSP - news) in September last year, to focus on drugs.

Infusion pumps provide exact dosage of intravenous drugs, sometimes by the millilitres per hour, and are used in medical areas such as intensive care, emergency care or neonatal care.

ADVERTISEMENT

Goldman Sachs (NYSE: GS-PB - news) is advising Pfizer on the divestment, the sources said.

Pfizer, Goldman, Fresenius and declined to comment while officials at Smiths were not immediately available for comment. (Editing by Harro ten Wolde)